BRUPHARM PHARMALAB
ActiveSummary
The computed 12-month bankruptcy probability of BRUPHARM PHARMALAB is 5.6% (elevated). The 2025 annual accounts show negative equity (-€102,855) and a net result of €10,043. Equity has been shrinking by about 55% per year since 2022. Its solvency ranks better than 8% of 9,845 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency signals. The KBO does carry 1 administrative register entry.
Overview
Overview
Official details
Source: KBO- Status
- Active since 03-05-2022 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460and 3 others
- Establishment unit
- 2.334.563.039 7011 Mons, since 15-07-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 16-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 5.6%
- Turnover
- €175,274
- ▲ 251%
- Profit
- €10,043
- Equity
- -€102,855
- ▲ 8.9%
- Total assets
- €298,430
- ▲ 22.4%
- Staff
- ≈ 1.2 FTE
- estimated
- Negative equity on 31-12-2025
- 2025 accounts filed 61 days after the deadline
Score breakdownraises riskLast filed accounts filed 61 days late; 3 of the last 3 accounts lateEx-officio strike-off in the KBOFounded in 2022Liquidity: current ratio 0.38, cash €3,496Show the evidence
Checked score
About 6 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 6% of them on solvency, 4% on liquidity, 75% on profitability and 80% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 4 accounts on average 222 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (1)
Financials
Financials · financial year 2025, abbreviated format
2025 annual accounts filed 61 days after the deadline Filed on 30 September 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00540376.
Annual accounts 2025 filed on 30-09-2026 at the NBB all 4 filings
2022 to 2025, 4 financial years
The operating result for 2025 is a loss of €352, smaller than the loss of €44,559 in 2024.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Wholesale trade (NACE 46). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
- 2025 Turnover +251% on 2024. The accounts now follow the abbreviated format, last year the micro format.
Investments
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Tangible fixed assets | €1,115 | - | - | €645 |
| Intangible fixed assets | €300,000 | - | - | - |
| Depreciation and write-downs of the year | €23,358 | €37,849 | €37,849 | €37,900 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Turnover70 | €58,722 | €46,657 | €49,927 | €175,274 | ▲ 251% |
| Goods, raw materials, services and sundry goods60/61 | €72,485 | €86,192 | €49,559 | €89,444 | ▲ 80.5% |
| Remuneration, social security and pensions62 | €17,550 | €34,328 | €8,965 | €47,496 | ▲ 430% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €23,358 | €37,849 | €37,849 | €37,900 | ▲ 0.1% |
| Other operating charges640/8 | €348 | - | €850 | €947 | ▲ 11.4% |
| Gross operating margin9900 | -€13,621 | -€39,506 | €3,105 | €85,990 | ▲ 28× |
| Operating profit (loss)9901 | -€54,877 | -€111,683 | -€44,559 | -€352 | ▲ 99.2% |
| Financial income75/76B | €131 | - | - | €11,564 | - |
| Recurring financial income75 | €131 | - | - | €11,564 | - |
| Financial charges65/66B | €354 | €1,026 | €530 | €1,169 | ▲ 121% |
| Recurring financial charges65 | €354 | €1,026 | €530 | €1,169 | ▲ 121% |
| Profit (loss) for the period before taxes9903 | -€55,100 | -€112,709 | -€45,089 | €10,043 | - |
| Profit (loss) for the period9904 | -€55,100 | -€112,709 | -€45,089 | €10,043 | - |
| Profit (loss) for the period to be appropriated9905 | -€55,100 | -€112,709 | -€45,089 | €10,043 | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €377,437 | €308,771 | €243,802 | €298,430 | ▲ 22.4% |
| Fixed assets21/28 | €277,756 | €239,907 | €202,059 | €164,805 | ▼ 18.4% |
| Intangible fixed assets21 | €276,781 | €239,281 | €201,781 | €164,281 | ▼ 18.6% |
| Tangible fixed assets22/27 | €975 | €627 | €278 | €524 | ▲ 88.5% |
| Plant, machinery and equipment23 | €710 | €430 | €149 | €0 | ▼ 100% |
| Furniture and vehicles24 | €265 | €197 | €129 | €524 | ▲ 307% |
| Current assets29/58 | €99,681 | €68,864 | €41,744 | €133,626 | ▲ 220% |
| Stocks and contracts in progress3 | €13,263 | €8,138 | €6,412 | €6,212 | ▼ 3.1% |
| Stocks30/36 | €13,263 | €8,138 | €6,412 | €6,212 | ▼ 3.1% |
| Amounts receivable within one year40/41 | €63,758 | €58,404 | €35,255 | €73,918 | ▲ 110% |
| Trade receivables40 | €58,722 | €55,723 | €35,255 | €25,255 | ▼ 28.4% |
| Other amounts receivable41 | €5,036 | €2,681 | - | €48,663 | - |
| Cash at bank and in hand54/58 | €22,659 | €2,323 | €77 | €3,496 | ▲ 45× |
| Deferred charges and accrued income490/1 | - | - | - | €50,000 | - |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €377,437 | €308,771 | €243,802 | €298,430 | ▲ 22.4% |
| Equity10/15 | €44,900 | -€67,809 | -€112,898 | -€102,855 | ▲ 8.9% |
| Contributions10/11 | €100,000 | €100,000 | €100,000 | €100,000 | = |
| Capital10 | €100,000 | €100,000 | €100,000 | €100,000 | = |
| Issued capital100 | €100,000 | €100,000 | €100,000 | €100,000 | = |
| Profit (loss) carried forward14 | -€55,100 | -€167,809 | -€212,898 | -€202,855 | ▲ 4.7% |
| Amounts payable17/49 | €332,537 | €376,580 | €356,701 | €401,286 | ▲ 12.5% |
| Amounts payable within one year42/48 | €332,537 | €376,580 | €356,701 | €348,662 | ▼ 2.3% |
| Trade debts44 | €11,941 | €38,550 | €24,986 | - | - |
| Suppliers440/4 | €11,941 | €38,550 | €24,986 | - | - |
| Taxes, remuneration and social security45 | €9,588 | €31,467 | €18,321 | €37,655 | ▲ 106% |
| Taxes450/3 | €524 | €1,758 | - | €37,655 | - |
| Remuneration and social security454/9 | €9,064 | €29,708 | €18,321 | - | - |
| Other amounts payable47/48 | €311,008 | €306,563 | €313,394 | €311,007 | ▼ 0.8% |
| Accrued charges and deferred income492/3 | - | - | - | €52,624 | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€55,100 | -€112,709 | -€45,089 | €10,043 | - |
| + Depreciation and write-downs630 | €23,358 | €37,849 | €37,849 | €37,900 | ▲ 0.1% |
| Operating cash flow (approximation) | -€31,742 | -€74,860 | -€7,240 | €47,942 | - |
| Investment in fixed assets (approximation) | - | €0 | €0 | -€645 | - |
| Change in cash | - | -€20,337 | -€2,246 | €3,419 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 516 companies had the same profile as BRUPHARM PHARMALAB has now. Two years later, 4.5% had gone bankrupt and 91.9% were still going.
- Micro
- 2 to 5 years old
- negative equity
- a profit under 5% of the balance sheet
Another 1.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of BRUPHARM PHARMALAB itself: 5.6% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 516 companies, not a prediction for BRUPHARM PHARMALAB. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Board & ownership
Directors
Owners and capital
Owners
Articles of association
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Nommés avec ou sans limitation de durée, Article10”“Article12, portée aux frais généraux,indépendamment des frais de représentation,voyages et déplacements”
Articles of association, deed of 05-05-2022 (in French)
Network & group
BRUPHARM PHARMALAB shares no director with another company.
Connections & network
1 current directorThe network starts from the directors of BRUPHARM PHARMALAB. Every other company they run is a node.
Timeline
Acts, filings and financial milestones
05-05
Gazette deed
IncorporationAppointment: VANDECAUTER Eric Christian Charles Jean Franz (administrateur non statutaire) · Founder · Founding capital13 points ▸
- Founder, LAITAT Thierry Michel Jacques (comparant)
- Founder, TATARU Simona (comparant)
- Founder, VANDECAUTER Olivier Charles Guy (comparant)
- Founder, VANDECAUTER Eric Christian Charles Jean Franz (comparant)
- Incorporation, “BRUPHARM PHARMALAB” (deed in French)
- Founding capital, €100,000
- Other provision, “arrêt des statuts, arrêter les statuts” (deed in French)
- Other provision, “premier-exercice-premiere-assemblee-ordinaire”, 31-12-2022 (deed in French)
- Registered office clause, “7011 Ghlin,Route de Wallonie,140” (deed in French)
- Board rule, 1
- Director appointment, VANDECAUTER Eric Christian Charles Jean Franz (administrateur non statutaire)
- Other provision, “commissaire, parenthese-ellipsis” (deed in French)
- The act holds 1 more point.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
NACEBEL 2025Codes under NACEBEL 2008
5 activities
- L’achat,la vente,la fabrication,l’importation,l’exportation,la représentation de produits médicaux,pharmaceutiques,cosmétiques,vétérinaires et alimentaires et toutes autres marchandises,la prestation de soins dentaires
- La pratique de l’art dentaire au sens le plus large en ce compris les prothèses ou autres dérivés liés à la pratique du soin dentaire ainsi que la pratique de la dentisterie holistique(naturopathie,aromathérapie,phytothérapie,gemmothérapie,homéopathie,élixirs floraux et minéraux,occlusodontie,posturodontie,électro-accupuncture)
- L’acquisition,l’exploitation et la concession de tous les droits intellectuels liés aux activités ci-dessus
- L’import et l’export,l’achat,la vente,la distribution de matières premières pharmaceutiques et alimentaires
- L’organisation de manifestations scientifiques,en ce compris l’organisation de formation à caractère professionnel sous toutes leurs formes que ce soient des séminaires,conférences,cours,voyages d’études ou autres
Invoicing and payment
Financial year and general meeting
Accounts at the NBBRecognitions · licences · registrations
Food safety, FASFC
1 siteSites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 53030G0552/00C000 | Wallonia | 2.3 ha | 1 · 5,751 m² | 8.6 m · 2 |